Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
FSTX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.20
N/A
-1.52
vs -1.12
Q3.20
N/A
-1.24
vs -1.68
Q4.20
N/A
-0.50
vs NA
Q1.21
N/A
-1.08
vs -1.96
Q2.21
N/A
-0.92
vs -1.52
Q3.21
N/A
-0.52
vs -1.24
Q4.21
+196%
0.48
vs -0.50
Q1.22
N/A
-0.57
vs -1.08
Q2.22
N/A
-0.88
vs -0.92
Q3.22
N/A
-0.84
vs -0.52
Sales Growth
YoY
Current
Estimates
Q2.20
NA
543K vs NA
Q3.20
NA
9.2M vs NA
Q4.20
NA
163K vs NA
Q1.21
+115%
2.9M vs 1.4M
Q2.21
-100%
NA vs 543K
Q3.21
-92%
751K vs 9.2M
Q4.21
+10636%
17.5M vs 163K
Q1.22
-13%
2.6M vs 2.9M
Q2.22
NA
NA vs NA
Q3.22
+50%
1.1M vs 751K
Return on Equity
QoQ
Q4.20
-20%
-0.20
vs -0.19
Q1.21
-28%
-0.28
vs -0.20
Q2.21
-16%
-0.16
vs -0.28
Q3.21
-12%
-0.12
vs -0.16
Q4.21
+5%
0.05
vs -0.12
Q1.22
-14%
-0.14
vs 0.05
Q2.22
-27%
-0.27
vs -0.14
Q3.22
-32%
-0.32
vs -0.27
Institutionnal Ownership
QoQ
Q1.21
25
25
vs 20
25%
Q2.21
42
42
vs 25
68%
Q3.21
42
42
vs 42
NA
Q4.21
46
46
vs 42
10%
Q1.22
37
37
vs 46
-20%
Q2.22
56
56
vs 37
51%
Q3.22
56
56
vs 56
NA
Q4.22
65
65
vs 56
16%
zacks.com
8 hours ago
benzinga.com
9 hours ago
seekingalpha.com
10 hours ago
zacks.com
10 hours ago
zacks.com
11 hours ago
seekingalpha.com
16 hours ago
Forecast
No Data Available
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
Laidlaw
initialisePrevious: Not converted
2021-03-25
Now: Buy
H.C. Wainwright
initialisePrevious: Not converted
2021-03-01
Now: Buy
Relative Strength
FSTX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
NASDAQ
Unprofitable
Unprofitable
Relative Strenght
96
Volume Buzz
-100%
Earning Acce
No
Dist 52w H.
0%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How FSTX compares to sector?
FSTX
-4x